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Abstract
Background: Schistosomiasis is one of the most important neglected tropical diseases. If unrecognised and
untreated, the chronic infection can lead to irreversible complications.
Methods: Retrospective observational study aimed at describing clinical history, laboratory findings and imaging
presentation of imported schistosomiasis diagnosed at the Centre for Tropical Diseases, Sacro Cuore Don Calabria
Hospital of Negrar, Verona, Italy from 2010 to 2014. The aim of our study was to assess differences in demographic
characteristics, clinical presentation, laboratory data and ultrasound findings between immigrants/visiting friends
and relatives (VFR) from endemic countries (endemic group) and expatriates/travellers (non-endemic group).
Results: A total of 272 patients were retrieved: 234 in the endemic and 38 in the non-endemic group. Most of the
patients acquired schistosomiasis in Africa (97.4%). Symptoms were reported by 52.9% of the patients; abdominal
pain (36%), macroscopic hematuria (11.3%), and genito-urinary symptoms (7.4%) being the most frequently
reported. Increased IgE and blood eosinophilia were observed in 169 (63.8%) and 130 (47.8%) patients, respectively.
The proportion of positive serology was 250/272 (91.9%).The Circulating Cathodic Antigen CCA for Schistosoma
mansoni was positive in 14/61 individuals (23%). At microscopy, infected subjects were 103/272 (37.9%). The species
of Schistosoma found were S. haematobium (47.6%), S. mansoni (46.6%) or both (5.8%). Schistosomiasis was
classified as confirmed in 103 (37.9%), probable in 165 (60.6%) and suspected in 4 (1.5%) cases using clinical
presentation, laboratory data and ultrasound findings. The infection was further classified based on organ
involvement: intestinal (17.9%), hepatosplenic (5.1%), urogenital (48.9%), and indeterminate (43.8%).
The comparative analysis of endemic and non-endemic patients highlighted differences in sex and age. Endemic
patients had more frequent ova identification (41.9% vs. 13.2%, P < 0.001) and increased IgE (70% vs. 26.3%,
P < 0.001) when compared with non-endemic. Multivariate analyses showed that younger age, abnormal ultrasound
findings and blood eosinophilia were significantly associated with positive microscopy (OR = 0.94, OR = 2.12,
OR = 1.98, respectively).
Conclusions: Symptoms, eosinophilia and abnormal ultrasound findings were present in about half of patients,
without differences between groups. Many patients had positive serology but negative microscopy, indicating that
schistosomiasis might be misdiagnosed. A combination of diagnostic tools may facilitate the diagnosis.
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Background
Schistosomiasis is one of the most important neglected
tropical diseases (NTDs), affecting over 258 million people
in 78 countries and causing 3.3 million disability-adjusted
life-years (DALYs) [1–4]. In sub-Saharan Africa, where
around 90% of the global cases occur, approximately
300 000 deaths annually have been estimated to be
caused by schistosomiasis [5].
Schistosoma mansoni and S. haematobium, the predom-
inating human species, cause intestinal schistosomiasis
(IS), hepatosplenic schistosomiasis (HSS) and urogenital
schistosomiasis (UGS), respectively [1, 6]. Infections
caused by S. intercalatum, S. japonicum and S. mekongi
are rarely reported, the latter two restricted to Asia [7].
People born in endemic countries are at high risk of
acquiring the infection during childhood, by contact
with contaminated freshwater. The exposure continues
in later years during domestic, recreational and eco-
nomic activities [1, 6]. As the lifetime of the adult
Schistosoma ranges from three to 40 years [8, 9], chronic
Schistosoma infections may remain clinically silent
(30–50% of the cases) [10] or cause relatively mild and
non-specific symptoms for years before eventually causing
severe, often unrecoverable organ damage such as fibrosis
and portal hypertension for S. mansoni, and obstructive
uropathy and hydronephrosis for S. haematobium [11–13].
Interestingly, the latter may lead to squamous cell carcin-
oma of the bladder [14, 15]. However, as clearly highlighted
by King [16], schistosomiasis should never be considered a
benign asymptomatic infection, as it always leads to
chronic tissue inflammation when left untreated. Unfortu-
nately, low-intensity infections may be easily missed by the
most widely available diagnostic test, that is microscopy.
Europe, and Italy in particular, is receiving an unprece-
dented flow of immigrants from sub-Saharan Africa, many
asylum seekers [17]. According to GeoSentinel [a network
of 41 tropical and travel medicine centres in 19 countries
around the world (http://www.istm.org/geosentinel)] from
1997 to 2009, schistosomiasis was diagnosed in 442 of
7629 (5.8%) migrants, predominantly non-refugees, 84%
of whom acquired the infection in Africa [18]. In these last
years, schistosomiasis prevalence among African refugees
and asylum seekers has been striking, albeit mostly
unrecognized as sensitive screening tools are generally un-
available [19–26].
Sub-Saharan Africa is a frequent destination reported by
European travellers [27]. In the EuroTravNet network of 18
European specialized centres (http://www.eurotravnet.eu),
which reported the travel-related illnesses of 32136
travellers from 2008 to 2012, schistosomiasis ranked 12th
with only 152 cases recorded [27]. Nevertheless, the risk of
schistosomiasis is not negligible in this group; often after a
single brief exposure to contaminated freshwater [28, 29].
Several cases series of schistosomiasis in European travel-
lers have been reported in recent years [30–36].
An unexpected outbreak of autochthonous urogenital
schistosomiasis cases occurred in Corsica, France during
the period 2013–2015 [37, 38], caused by a parasite gen-
etically related to S. haematobium from Senegal [39, 40].
The outbreak raised attention to a possible spread of
schistosomiasis in areas of Southern Europe [41–43]
where the intermediate host is present [44]. Hence,
surveillance on imported schistosomiasis in Europe, to-
gether with an increased professional awareness for this
NTD, are necessary [45].
This study reviews demographic data, travel history,
clinical and laboratory information, imaging and other
diagnostic findings of the largest case series of imported
schistosomiasis observed in a single site (the Centre for
Tropical Diseases, [CTD] Sacro Cuore Don Calabria
Hospital, Negrar, Verona) in Italy over a 5-year period.
Methods
Study design
Retrospective, observational study intended to review
patients diagnosed with schistosomiasis at CTD and to
assess differences between subjects born in endemic and
non-endemic countries.
Study population and data collection
The study was carried out at the CTD, a national referral
centre for tropical and parasitic diseases, between 1 January
2010 and 31 December 2014. Patients were included in the
study if they met diagnostic criteria for schistosomiasis, de-
scribed in the case definition paragraph. All patients were
treated with praziquantel 40 mg/kg for three consecutive
days. Patients lacking a written informed consent for collec-
tion of data and biological samples for study purposes were
excluded from the study.
For each included patient, we reviewed from a CTD
patient database the travel history, clinical and labora-
tory data, imaging, and other diagnostic procedure find-
ings. Data were analysed anonymously.
The study subjects were classified into two groups:
Endemic group: immigrants from countries where
schistosomiasis is endemic, differentiated into either im-
migrants, refugees or asylum seekers recently arrived in
Italy, or non-recent immigrants who had travelled to
their countries of origin for business purpose or visiting
friends or relatives (VFR);
Non-endemic group: Italians visiting endemic coun-
tries, including expatriates and short-term travellers
(tourists, students, business travellers).
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For the endemic group, the country of origin was re-
corded as the probable area of exposure. The period of
time going from the date of first arrival in Italy to the date
of diagnosis was defined as “elapsed time”. For the
non-endemic group, the country visited and the elapsed
time (days from the date of return to the date of diagnosis)
were recorded. If the patient reported possible exposure in
more than one endemic area for schistosomiasis, the
country of the longer exposure was selected, unless there
were clear indications for acquisition of the infection in a
different country.
The symptoms and signs included were abdominal pain,
defined as non-specific abdominal discomfort and pain, and
genito-urinary symptoms, comprehensive of urinary fre-
quency, dysuria and/or burning and/or painful ejaculation.
Additionally, Katayama syndrome, cough and gynaeco-
logical/andrological complaints were classified as other
symptoms, while the presence of blood in urine or stool was
recorded as macrohematuria or rectal bleeding, respectively.
Laboratory data
The blood test evaluation of each patient included blood
cell count and IgE quantitative nephelometry assay.
Blood eosinophilia was defined in case of absolute
eosinophil count (AEC) value ≥ 300 cell/μl and increased
IgE if total IgE value equal or above the upper normal
limit (≥ 120 IU/ml).
Serum samples were evaluated for the detection of
antibodies against Schistosoma spp. by an indirect im-
munofluorescence (IFAT) using whole cercarial antigen
(DiaTeSt-Cercaria FAT) from January 2010 to September
2012. An Enzyme-linked immunosorbent assay (ELISA)
using S. mansoni soluble egg antigens (Bordier Affinity
Products, Crissier, Switzerland) was introduced from
February 2012 to December 2014. Other immunodiagnos-
tic methods were used to detect the presence of Strongy-
loides stercoralis and viral infections: an in-house indirect
immunofluorescence (IFAT) for S. stercoralis [46] and
enzyme-linked immunosorbent assay (ELISA, Beckmann)
for HIV, HCV and HBsAg with a confirmatory test in case
of a positive result.
Finally, since March 2014, urine circulating cathodic
antigen (CCA) dipstick test for S. mansoni was available:
from a single urine sample a 50 μl aliquot was used to
test for the presence of schistosoma CCA with a com-
mercially available immuno-chromatographic dipstick
test following the manufacturer’s instruction (NADAL
CCA Bilharzia test, Germany).
Microscopy examination (100 ×) for ova and parasites,
after formol-ether concentration on three stool samples
collected in alternate days was performed for each pa-
tient together with an urine microscopy examination
(100 ×) after micropore filtration for S. haematobium on
the sediment of at least 20 ml end-stream urine. One to
three urine samples were obtained from 10 am to 12 am
over consecutive days. Microscopy detection of eggs in bi-
opsy of any tissue specimen was also performed, if done.
Ultrasounds and other diagnostic procedures
The results of abdomen ultrasounds and other invasive
tests, such as liver biopsy, were recorded. In particular, an
ultrasound finding was considered abnormal in the case
of: liver or spleen enlargement (a rounding of the inferior
liver margin, and bipolar spleen diameter > 12 cm),
periportal thickening, cirrhosis, portal hypertension,
bladder wall thickening or lesions (calcification or small
parietal vegetation), an abnormality in the urinary tract
(ureter dilatation or hydronephrosis) or lesions compatible
with liver or bladder cancer [47–49].
Two abnormal ultrasound patterns that likely corre-
lated to the schistosomiasis were recorded:
Urogenital (UG) pattern: bladder wall thickening or
lesions, an abnormality of the urinary tract or lesions
compatible with bladder cancer.
Hepatosplenic (HS) pattern: presence of periportal
thickening, cirrhosis or portal hypertension.
Case definition
Based on clinical, laboratory, and ultrasounds findings,
we operationally classified schistosomiasis as [32, 37]
confirmed schistosomiasis in case of retrieval of Schisto-
soma ova (either in stool, urine or specimen biopsy).
Whenever a patient had positive urine CCA and/or ser-
ology test without evidence of ova, the case was classified
as having probable schistosomiasis. A possible schisto-
somiasis was defined with abnormal ultrasound patterns
(as defined previously) and/or total IgE ≥ 1000 IU/ml,
without evidence of ova or with negative urine CCA or
serology test [32].
Additionally, based on signs of organ involvement, we
differentiated schistosomiasis into intestinal schistosomiasis
(IS) if ova of S. mansoni or S. mekongi or S. japonicum were
found in the stool or in the rectal biopsy. If ova of S. man-
soni or S. mekongi or S. japonicum were found in the liver
biopsy or if the ultrasounds revealed an HS pattern (as de-
fined above) the case was considered as hepatosplenic
schistosomiasis (HSS). Urogenital schistosomiasis (UGS)
was diagnosed if ova of S. haematobium were found in the
urine or bladder biopsy, if the patient reported macroscopic
hematuria or genito-urinary symptoms or if the ultrasound
revealed a UG pattern (as defined above). In absence of
ova, positive serology and/or urine CCA test, and without
any ultrasound patterns or specific symptoms, the patient
was considered having indeterminate schistosomiasi (I).
Statistical analysis
Descriptive statistics were used to analyse the character-
istics of the entire cohort and then separately for
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individuals born in endemic areas and individuals born
in Italy. Categorical variables were reported as frequen-
cies and proportions, while quantitative variables were
presented as median (inter-quartile range, IQR).
The association between the aforementioned variables was
then investigated through univariate statistical tests, such as
the Chi-squared test, Fisher test and Kolmogorov-Smirnov
test, as considered appropriate. Lastly, multivariate logistic
regression models were fitted to assess the impact of all
covariates on the probability of contracting symptoms
related to schistosomiasis and on the probability of
detecting ova in any specimen. All statistical analyses were
conducted using R, version 3.3.3 [50].
Results
Demographic data and travel history
Demographic data and travel-related information are de-
tailed in Table 1. Of the 272 subjects, 215 (79%) were male
and the median age was 30 (IQR:25–39.5). Most subjects
(86%) were immigrants, of whom, 76.1% (178 subjects)
were either refugees or asylum seekers, whereas in the
non-endemic group (38 subjects) travellers and expatriates
were equally represented (19 subjects in both sub-groups).
The male gender was more represented in the immigrant
group than in the travellers of the non-endemic group
(82.5 vs 57.9%, P = 0.002). The median age of the immi-
grants was significantly lower than that of the patients in
the non-endemic group (28 vs 41.5 years, P < 0.001).
Almost all cases originated from Africa (n = 261, 97.4%),
mostly Western (n = 188, 69.1%), Eastern (n = 41, 15.1%)
and Central (n = 29, 10.7%); only a few cases were from
South America (n = 4, 1.5%), Asia and Oceania (n = 3, 1%).
The most represented countries (not reported in Table)
were Mali (19%), Ghana (14%), Ivory Coast (7%), Senegal
(6%), Nigeria (5%), Tanzania (5%) and Ethiopia (4%). The
countries of probable exposure are shown in detail in Fig. 1.
The median elapsed time was 197 (67.5–526.5) days.
Clinical presentation and laboratory characteristics
One hundred and forty-four (52.9%) patients presented
at least one symptom suggestive of schistosomiasis
(Table 2). The most common symptom was abdominal
pain (36%), followed by macroscopic hematuria (11.3%),
other genito-urinary symptoms (7.4%), rectal bleeding
(1.5%), and cough (1.1%). None of the patients were
diagnosed with Katayama syndrome. No significant
differences were found in the symptom distribution
between the two main groups.
HIV infection (n = 4, 1.5%), chronic hepatitis B
(n = 36, 13.2%), and HCV infection (n = 8, 2.9%) were
exclusively found in the endemic group. One patient had
the co-infection schistosomiasis/HCV/HBV.
Forty-nine subjects (22.8%) had other helminth
infections, including both S. stercoralis diagnosed by
immunodiagnostic method, as well as other intestinal
helminths, diagnosed by parasitological method.
The median value of IgE and absolute eosinophil count
were 304.5 IU/ml (IQR: 52.5–924.5) and 290 cell/μl
(IQR: 160–540), respectively. Increased IgE was observed
in 169 subjects (63.8%), while peripheral eosinophilia was
present in 130 (47.8%) patients. The IgE level was more
frequently raised in the endemic group (70 vs. 26.3%,
P < 0.001), while no significant difference was found
in the proportion of eosinophilia.
Schistosoma ova were detected in 103 subjects (37.9%):
S. haematobium in 49 (47.6%), S. mansoni in 48 (46.6%)
and both species in 6 subjects (5.8%). The ova were found
in stools in 50 cases (18.4%), urine in 52 (19.1%), and
tissue biopsy in 12 (4.4%), specifically: lungs (n = 2), liver
(n = 2), uterus (n = 1), colon (n = 1) and appendix (n = 1).
The immigrants were more likely to have ova de-
tected than the non-endemic subjects (41.9 vs. 13.2%,
P < 0.001).
Serology for schistosomiasis was positive in 250 sub-
jects (91.9%) with no significant differences between the
Table 1 Baseline demographic of the cohort and stratified by endemicity of provenience
Characteristica Entire cohort Area of origin p-valueb
N, % Endemic Non-endemic
Total 272 234 (86.0) 38 (14.0)
Median age, years (IQR) 30 (25–39.5) 28 (24–38) 41.5 (34–63.7) < 0.001*
Male, N (%) 215 (79.0) 193 (82.5) 22 (57.9) 0.002*
Median elapsed time, days (IQR) 197 (67.5–526.5) 209 (71–576.5) 120.5 (52–392.7) 0.327
Continent of Exposure, N (%)
Africa 261 (97.4) 232 (99.1) 29 (85.3) < 0.001*
America 4 (1.5) 2 (0.9) 2 (5.9) 0.089
Asia and Oceania 3 (1.1) 0 (0.0) 3 (8.8)
Abbreviations: IQR Inter-quartile range
aRelative frequencies for each variable are obtained on the sub-population for which information was available
bCalculation of the P-value was done through Kolmogorov-Smirnov test for the difference in the distribution of age and elapsed time, whereas Fisher’s exact test
was used for all dichotomous variables. Finally, the Chi-Squared test was used to test the difference in the distribution among diagnoses types
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groups. IFAT serology was used in 163 cases (59.9%),
while 109 patients (40.1%) were tested by ELISA test.
Eighteen of 103 patients (17.5%) with schistosoma ova
identified by microscopy were negative by serology. Eleven
of these 18 patients (61.1%) had S. haematobium infection.
Urine CCA test was found positive in 14 of 61 (23%)
patients evaluated with this test.
Ultrasound findings and patterns
Ultrasounds showed abnormalities in 124 of 254 sub-
jects examined (48.8%), including: liver enlargement
(n = 64, 25.2%), spleen enlargement (n = 35,13.8%), cirrho-
sis (n = 8, 3.2%), bladder lesions (n = 22, 8.7%) (Fig. 2),
thick bladder wall (n = 45, 17.7%), portal hypertension
(n = 6, 2.4%) and periportal thickening/fibrosis (n = 6, 2.4%).
In summary, 52 (20.5%) patients’ ultrasound findings were
compatible with the UG pattern and 13 (5%) with the HS
pattern, without differences between the groups (data
not shown).
Thirty-six of 103 (34.9%) patients with schistosomiasis
confirmed by microscopy had an abnormal ultrasound
pattern: 30 (29.1%) UG, three (2.9%) HS, and three
patients (2.9%) both patterns. Differently, in patients
with schistosomiasis with positive serology test without
evidence of ova, 21 (12.7%) had ultrasound alterations:
five (3%) HS and 16 (9.7%) UG pattern.
Globally, rates of ultrasound abnormalities found in
confirmed schistosomiasis and in patients with positive
serology only (34.9% vs. 12.7%) were statistically differ-
ent (P < 0.001).
Case definition
According to the clinical features, the patients were clas-
sified as follows: 133 (48.9%) with UGS, 48 (17.9%) with
IS, 13 (5.1%) with HSS and 110 (43.8%) with indetermin-
ate schistosomiasis. The diagnosis was confirmed in 103
cases (37.9%), probable in 165 (60.6%), and possible in
four (1.5%) (Table 2).
Univariate and multivariate analyses
Table 3 shows the results of the univariate and multi-
variate analyses on the association between microscopic
ova identification and demographic characteristics, as
well as laboratory/ultrasound findings. Younger age,
abnormal ultrasound findings and blood eosinophilia were
significantly associated with a positive microscopy
(OR = 0.94, 95% CI: 0.91–0.97; OR = 2.12, 95% CI:
1.15–3.96; OR = 1.98, 95% CI: 1.03–3.83, respectively).
Discussion
Sentinel surveillance data for imported schistosomiasis in
Europe has been available since 1997 through the
European Network for Tropical Medicine and Travel
Health (TropNet) [32, 36] and the GeoSentinel Surveillance
Network [34]. Moreover, a few observational studies were
performed by individual tropical centres in Munich
(Germany) [30], Barcelona (Spain) [31], Amsterdam (the
Netherlands) [33] and London (United Kingdom) [35].
Most of our cases (96%) were imported from the
African continent, primarily West Africa, similarly to all
studies mentioned above [30–36]. A peculiarity of our
study is the high proportion of migrants (86%), of whom
more than two-thirds were young male refugees and asy-
lum seekers (all from Africa), in contrast with travellers
and expatriates. The recent high flow of asylum seekers
from Africa to Europe (and particularly to Italy) largely
explains the demographic characteristics observed [17].
Previous screening studies conducted on migrant pop-
ulations in Europe found a questionably low prevalence
of schistosomiasis, probably depending on the diagnostic
tools used [19, 21, 23–25]. Indeed, only about 40% of
our patients included in the endemic group had a diag-
nosis of confirmed schistosomiasis, and therefore, had
Fig. 1 Geographical distribution of the places of exposure (data are the number of patients)
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we relied on ova identification only, the number of cases
diagnosed would have been much lower. On the other
hand, we have recently shown that the sensitivity of ova
detection is comparatively low [26]. It might be argued
that a number of false positive cases may be comprised
among those classified as “probable” on the basis of ser-
ology. However, the specificity of serology is high, and so
is that of CCA test [26] hence the number of false posi-
tive cases (if any) is probably limited.
Almost half of the patients were asymptomatic. These
data concur with other studies, reporting proportions
ranging from 36 to 50%, depending on the population
analysed [36]. Coltart et al. described a more frequently
asymptomatic presentation in the non-endemic group
[35]: the most frequent symptom reported was abdom-
inal pain and, although almost half of the cases were
considered UGS, only 11% of the patients reported
macroscopic haematuria. Differently from Coltart’s work,
several studies showed differences in clinical presenta-
tion between the endemic and the non-endemic groups.
Lingscheid et al. found that Europeans presented more
frequently fever and musculoskeletal symptoms, whereas
Table 2 Clinical characteristics and laboratory results of the cohort and stratified by endemicity of provenience
Characteristica Entire cohort Area of origin p-valueb
Endemic Non-endemic
Total, N (%) 272 234 (86.0) 38 (14.0)
Symptoms presence, N (%) 144 (52.9) 124 (52.9) 20 (52.6) 1
Abdominal pain 98 (36.0) 85 (36.3) 13 (34.2) 0.857
Genito-urinary 20 (7.4) 16 (6.8) 4 (10.5) 0.625
Macro-hematuria 25 (11.3) 22 (9.4) 3 (7.9) 1
Rectal bleeding 4 (1.5) 4 (1.7) 0 (0)
Cough 3 (1.1) 3 (1.3) 0 (0)
Positive microscopy, N (%) 103 (37.9) 98 (41.9) 5 (13.2) < 0.001*
Ova in stools 50 (18.4) 48 (20.5) 2 (5.3) 0.020*
Ova in urine 52 (19.1) 49 (20.9) 3 (7.9) 0.070
Ova in biopsy 12 (4.4) 11 (4.7) 1 (2.6) 1
Schistosoma species, N (%)
S.haematobium 49 (47.6) 46 (46.9) 3 (60.0) 0.102
S.mansoni 48 (46.6) 46 (46.9) 2 (40.0) 0.037*
Both 6 (5.8) 6 (6.2) 0 (0.0)
Positive serology, N (%) 250 (91.9) 213 (91.0) 37 (97.4) 0.332
Increased IgEc, N (%) 169 (63.8) 159 (70.0) 10 (26.3) < 0.001*
Blood eosinophilia, N (%) 130 (47.8) 115 (49.1) 15 (39.5) 0.297
Other helminths, N (%) 49 (22.8) 44 (18.8) 5 (13.2) 0.499
Abnormal Ultrasound, N (%) 124 (48.8) 110 (50.2) 14 (40.0) 0.280
Infection Site, N (%)
IS 48 (17.9) 46 (20.0) 2 (5.4) 0.037*
HSS 13 (5.1) 13 (5.9) 0 (0)
UGS 133 (48.9) 120 (51.3) 13 (34.2) 0.056
I 110 (43.8) 88 (40.6) 22 (64.7) 0.009*
Diagnosis Type, N (%)
Confirmed 103 (37.9) 98 (41.9) 5 (13.2) 0.003*
Probable 165 (60.6) 133 (56.9) 32 (82.2)
Suspected 4 (1.5) 3 (1.2) 1 (2.6)
Abbreviations: IS Intestinal, HSS Hepato-splenic schistosomiasis, UGS Urogenital schistosomiasis, I Indeterminate
aRelative frequencies for each variable are obtained on the sub-population for which information was available
bCalculation of the P-value was done through different statistical tests. Namely, Kolmogorov-Smirnov test was used for testing the difference in the distribution of
age and elapsed time, whereas Fisher’s exact test was used for all dichotomous variables. Finally, the Chi-Squared test was used to test the difference in the
distribution among diagnoses
cTotal IgE value equal or above the upper normal limit (≥120 IU/ml)
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the non-endemic group complained more often of
haematuria, bloody diarrhoea and weight loss compatible
with chronic schistosomiasis [36]. The high proportion
of migrants in our series (86%, contrarily to other series
in which the tourists represented the vast majority),
along with the relatively long time elapsed from expos-
ure to presentation to hospital of both groups (7 months
in endemic and 4 months in non-endemic), probably ac-
counts for the absence of febrile cases compatible with
acute schistosomiasis [33, 34, 51]. Of note, a high pro-
portion of cases had already developed symptoms/signs
compatible with chronic schistosomiasis, and the treat-
ment probably permitted to prevent life-threatening
complications. However, almost half of the cases were
asymptomatic, so this parasitic infection would have
never be detected in this group if not systematically
searched, based on epidemiological criteria.
Eosinophilia was present only in the 47.8% of the
cases. Interestingly, a higher proportion (63.8%) of
subjects with increased IgE value was found, consistent
with a recent study performed in an endemic area for S.
mansoni [52]. In our study, some differences were found
in the laboratory findings of the two main groups. In
particular, a significantly higher proportion of patients
with raised IgE was found in the endemic group.
The proportion of patients with positive serology was
92%, whereas a confirmed parasitological diagnosis was
achieved in 38% of patients; among the latter, 18 cases
had negative serology. Worthy to note, the immunodiag-
nostic method was changed from IFAT to ELISA during
the course of the study due to availability constraints.
However, different studies showed similar sensitivity for
the two tests, that is higher for S. mansoni infection
[53, 54]. Indeed, in our study, most of the 18 confirmed
cases with negative serology (61%) had S. haematobium
infection, for which serology has sensitivity ranging from
21.4 to 71.4%. [53].
In line with the literature, we considered only microscopy
as gold standard for diagnosis [1]. The accuracy of CCA
test for S.mansoni is not optimal, especially in case of urin-
ary tract infections, hematuria, pregnancy and in young
children [55]. Furthermore, the test was available only in
the late stage of our study, and few results were available.
Abnormal US findings were present in about half of
the study subjects. Hepatomegaly or splenomegaly was
reported in 25.3 and 13.8% of cases, respectively, but of
course this can be due to causes other than schistosom-
iasis. Therefore, abdominal organomegaly was not
considered a sufficient criterion to define hepatosplenic
schistosomiasis in our cohort. We then probably
underestimated the proportion of HSS, especially in the
early stage, which is most susceptible to regression
after treatment.
Fig. 2 Pseudopolyp of the urinary bladder in an immigrant with
S. haematobium infection
Table 3 Crude and adjusted ORs for the association between patients’ characteristics and the risk of detection of ova in any specimena
Covariateb Ova present Ova absent Crude OR Adjusted OR (95% CI)c
Age 26 (21–32.5) 34 (27–44) 0.93 (0.90–0.95) 0.94 (0.91–0.97)
Male 91.3% 71.0% 4.22 (1.92–10.31) 2.04 (0.78–5.81)
Elapsed Time 184 (56–328) 209 (71–657) 0.99 (0.99–0.99) 1.00 (0.99–1.01)
Other Parasites 18.4% 17.5% 1.06 (0.53–2.11) 0.79 (0.36–1.70)
Endemics 95.2% 80.7% 4.66 (1.72–15.87) 2.08 (0.64–8.10)
Abnormal ultrasound 61.0% 41.0% 2.23 (1.30–3.89) 2.12 (1.15–3.96)
Symptoms presence 59.2% 50.0% 1.45 (0.86–2.46) 1.82 (0.98–3.42)
Increased IgEd 80.0% 53.7% 3.43 (1.87–6.49) 1.20 (0.53–2.72)
Blood eosinophilia 64.0% 37.3% 2.98 (1.74–5.15) 1.98 (1.03–3.83)
Abbreviations: OR odds ratio, CI confidence interval
aDue to the heterogeneity of provenience of patients, covariates such as exposure time could not be included in models
bRelative frequencies are presented here, whereas the median (interquartile range) is reported for Age and Elapsed Time
cAdjusted for every other covariate through a multivariate logistic regression model
dTotal IgE value equal or above the upper normal limit (≥ 120 IU/ml)
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Differently, thick bladder wall and bladder lesions,
both considered signs of S. haematobium infection, were
found in 17.7 and 8.7% of the cases, respectively, and
permitted to identify 20.5% patients with UGS.
No cases of liver or bladder cancer were found in
our study.
The higher rate of US abnormalities found in patients
with positive microscopy compared with patients with
positive serology only is not surprising. Serology can de-
tect a higher number of infections of low intensity, diffi-
cult to diagnose with stool/urine microscopy. Presumably,
these are stages of infection that may still cause organ
damage. Nevertheless, we cannot exclude some false posi-
tive results of serology, especially with regard to possible
previous infections and treatments [56]. Assessing the
efficacy (adequate dosage and duration) of previous
treatments is challenging, and so is evaluating possible
re-exposures occurred after treatment, particularly for
migrants at first arrival. In consideration of the short-term
treatment’s high tolerability, it is worth treating subjects
who are positive to serology only.
The association of ova identification with abnormal
US findings and with blood eosinophilia (Table 3) is
interesting, as it seems to suggest a correlation of these
findings with the parasitic load. Neither finding, how-
ever, can be considered a good predictor or excluder of
this infection, thus their clinical use is limited to poten-
tially raising the index of suspicion, particularly in
settings where accurate parasitological methods are not
often accessible, and only a few (if any) immunodiagnos-
tic methods are available.
On the other hand, we did not find any significant as-
sociation between symptoms and ova detection, a factor
which further supports the need for an active screening.
The association between younger age and positive mi-
croscopy confirms data already reported in the literature.
Precisely, in endemic settings, people are often exposed
to repeated infections during childhood and adolescence,
and gradually develop an efficient immune response
through time [52].
Our study has limitations, mainly due to its retrospect-
ive design. Firstly, we were not able to assess ova
intensity in cases confirmed by microscopy, because
these data had not been collected. Secondly, abdomen
US had been performed following standard, clinical rou-
tine, which means that we might have missed initial
forms of HSS or UGS. Finally, as mentioned above, the
serological test for schistosomiasis was changed during
the study period.
Conclusions
European clinicians need to be alerted about possible
cases of schistosomiasis in subjects from endemic coun-
tries, particularly from sub-Saharan Africa.
The gold standard test permitted to diagnose only
one-third of cases. Clinical and diagnostic presentation
can be silent in patients with schistosomiasis. Symptoms,
eosinophilia and abnormal US findings may raise the
index of suspicion both in patients born in endemic and
in non-endemic countries. The combination of different
diagnostic tools may facilitate the diagnosis and
allow the treatment of an infection that can lead to
severe complications.
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